Activity of temozolomide against human tumor colony-forming units

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1769-1774

  Raymond, Eric ^a   Izbicka, Elzbieta ^a   Soda, Hiroshi ^a   Gerson, Stanton L ^b   Dugan, Margaret ^c   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; TEMOZOLOMIDE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL DEATH; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT; CYTOTOXICITY; DEMETHYLATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR GROWTH;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL DIVISION; DACARBAZINE; DIGESTIVE SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS; UROGENITAL NEOPLASMS;

EID: 0030862884     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stevens, M., and Newlands, E. From triazines and triazenes to temozolomide. Eur. J. Cancer, 29A: 1045-1047, 1993.
2. Denny, B., Wheelhouse, R., Stevens, M., Tsang, L., and Slack, J. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
3. Friedman, H., Dolan, M., Pegg, A., Marcelli, S., Keir, S., Catino, J., Bigner, D., and Schold, S. J. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
4. Plowman, J., Waud, W., Koutsoukos, A., Rubinstein, L., Moore, T., and Grever, M. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res., 54: 3793-3799, 1994.
5. O'Reilly, S., Newlands, E., Glaser, M., Brampton, M., Rice-Edwards, J., Illingworth, R., Richards, P., Kennard, C., Colquhoun, I., and Lewis, P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer, 29A: 940-942, 1993.
6. Patel, M., McCully, C., Godwin, K., and Balis, F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 14: 461, 1995.
7. Bleehen, N., Newlands, E., Lee, S., Thatcher, N., Selby, P., Calvert, A., Rustin, G., Brampton, M., and Stevens, M. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
8. O'Reilly, S., Newlands, E., Stevens, M., Smith, D., Brampton, M., Slack, J., and Rustin, G. Temozolomide has activity against primary brain tumors, melanoma and mycosis fungoides. Br. J. Cancer, 65: (Suppl. 16): 13, 1992.
9. Bunn, P. J., Hoffman, S., Norris, D., Golitz, L., and Aeling, J. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann. Intern. Med., 121: 592-602, 1995.
10. Ames, M., Reid, J., Stevens, D., Rhodes, W., Nicholson, S., and Reaman, G. Temozolomide (TEM) pharmacokinetics in the Children's Cancer Group Phase I trial of TEM administered as a single oral dose on a daily ×5 schedule. Proc. Annu. Meet. Am. Assoc. Cancer. Res., 36: 236, 1995.
11. Eckardt, J., Weiss, G., Burris, H., Rodriguez, G., Fields, S., Rinaldi, D., Drengler, R., Dugan, M., Batra, V., and Von Hoff, D. Phase I and pharmacokinetic trial of SCH52365 (temozolomide) given orally daily × 5 days. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 14: 484, 1995.
12. Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., and Gibson, A. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
13. Secher, D., Burtles, S., Newell, D., and Connors, T. Phase I/II clinical trials of new cancer treatments: toxicological review of the Cancer Research Campaign experience. Proc. Annu. Meet. Am. Assoc. Cancer Res., 35: 460, 1994.
14. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
15. Stevens, D., Reid, J., Rhodes, W., Rubin, J., and Ames, M. Pharmacokinetics of MTIC and other temozolomide (TEM) metabolites following administration of TEM to patients with advanced cancer. Proc. Annu. Meet. Am. Assoc. Cancer Res., 36: 364, 1995.
16. Baer, J., Freeman, A., Newlands, E., Watson, A., Rafferty, J., and Margison, G. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer, 67: 1299-1302, 1993.
17. D'Atri, S., Piccioni, D., Castellano, A., Tuorto, V., Franchi, A., Lu, K., Christiansen, N., Frankel, S., Rustum, Y., and Papa, G. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann. Oncol., 6: 389-393, 1995.
18. Mitchell, R., and Dolan, M. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol., 32: 59-63, 1993.
19. Taverna, P., Catapano, C., Citti, L., Bonfanti, M., and D'Incalci, M. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anti-Cancer Drugs, 3: 401-405, 1992.
20. Tisdale, M. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol., 36: 457-462, 1987.
21. Wedge, S., Porteous, J., May, B., and Newlands, E. Potentiation of temozolomide cytotoxicity by an inhibitor of alkylguanine-DNA alkyltransferase. J. Cell. Biochem., 21 (Suppl. A): 297, 1995.
22. Wedge, S., and Newlands, E. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer, 73: 1049-1052, 1996.
23. Tentori, L., Graziani, G., Gilberti, S., Lacal, P., Bonmassar, E., and D'Atri, S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia (Baltimore), 9: 1888-1895, 1995.
24. Pera, M., Koberle, B., and Masters, J. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br. J. Cancer, 71: 904-906, 1995.
25. Brent, T., Houghton, P., and Houghton, J. O6 alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-trans-4-methyl-cyclohexyl)-1-nitrosourea. Proc. Natl. Acad. Sci. USA, 82: 2985-2989, 1985.
26. O'Reilly, S., Newlands, E., Brown, G., Brady, F., Connors, T., Jones, T., and Price, P. Investigation of human in vivo tissue and tumor pharmacokinetics and mechanism of action of temozolomide. Br. J. Cancer, 69 (Suppl. 21): 23, 1994.
27. Von Hoff, D., Marshall, M., Chacon, D., Leal, B., Rodriguez, F., Drabek, S., Garcia, R., and Brown, B. Cloning of primary human tumor colony forming units in glass capillaries. J. Tissue Cult. Methods, 13: 125-131, 1992.
28. Von Hoff, D. Human tumor stem cell assay. Curr. Ther. Hematol-Oncol., 3: 365-367, 1987.
29. Alberts, D., and Chen, H. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: S. E. Salmon (ed.), Human Tumor Stem Cells, pp. 351-359. New York: Alan R. Liss, 1980.
30. Tentori, L., Leonetti, C., and Aquino, A. Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of α-6 integrin phosphorylation. Eur. J. Cancer, 31A: 746-754, 1995.
31. Calvert, H., Newlands, E., Brampton, M., Bleehan, N., and Abrahamsen, D. A Phase II study of temozolomide in malignant melanoma. Ann. Oncol., 5 (Suppl. 8): 172, 1995.
32. Belanich, M., Randall, T., Pastor, M., Kibitel, J., Alas, L., Dolan, M., Schold, S. J., Gander, M., Lejeune, F., Li, B., White, A., Wasserman, P., Citron, M., and Yarosh, D. Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother. Pharmacol., 37: 547-555, 1996.
33. D'Incalci, M., Taverna, P., Erba, E., Filippeschi, S., Potenza, D., Mariani, L., Citti, L., and Catapano, C. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of mouse L1210 leukemia. Anticancer Res., 11: 115-122, 1991.
34. Lee, S., Thatcher, N., Crowther, D., and Margison, G. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer, 69: 452-456, 1994.